Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
The British Journal of Surgery
|
November 9, 2017
International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction
Z E Winters, M Afzal, C Rutherford, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
V Bjelic-Radisic, F Cardoso, D Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M Gnant, B Mlineritsch, H Stoeger, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
EJNMMI Research
|
April 20, 2016
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016
W Langsteger, A Rezaee, W Loidl, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
The British Journal of Surgery
|
November 9, 2017
International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction
Z E Winters, M Afzal, C Rutherford, et al.
ESMO Open
|
June 11, 2026
First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
M Schmidt, M Thill, J Rey, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
V Bjelic-Radisic, F Cardoso, D Cameron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M Gnant, B Mlineritsch, H Stoeger, et al.
ESMO Open
|
April 25, 2024
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
P Meyer-Wilmes, J Huober, M Untch, et al.
ESMO Open
|
August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)
M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)
O Gluz, U Nitz, M Christgen, et al.
ESMO Open
|
June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M J Naughton, D M Zahrieh, M Gnant, et al.
EJNMMI Research
|
April 20, 2016
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016
W Langsteger, A Rezaee, W Loidl, et al.
Page
of 2